Femara 2.5 mg Alternative – Femroz (Letrozole) 2.5 mg | Everest Pharmaceuticals

Femroz 2.5 mg Tablet, manufactured by Everest Pharmaceuticals Ltd., Bangladesh, contains Letrozole 2.5 mg, the same active ingredient and strength found in the original branded medicine Femara by Novartis.

Femroz is a nonsteroidal aromatase inhibitor used in the hormonal treatment of certain types of breast cancer in postmenopausal women.

Originator Reference: Femara 2.5 mg (Novartis)
Alternative Brand: Femroz 2.5 mg (Everest Pharmaceuticals)
Generic Name: Letrozole
Strength: 2.5 mg
Dosage Form: Oral Tablet
Prescription Status: Prescription Only

Although both products contain the same active ingredient and strength, therapeutic equivalence and substitution eligibility should be confirmed by an authorized healthcare professional according to applicable regulatory requirements.

Active Ingredient and Composition

Each Femroz tablet contains Letrozole 2.5 mg as its active pharmaceutical ingredient.

Letrozole is a third-generation, nonsteroidal aromatase inhibitor used in the hormonal management of breast cancer. It is administered orally and acts by inhibiting the enzyme responsible for estrogen synthesis.

The complete inactive ingredient composition should be confirmed from the manufacturer’s official product documentation.

Therapeutic Indications and Uses

Letrozole is used in several clinical settings involving breast cancer in postmenopausal women.

1. Early Hormone Receptor-Positive Breast Cancer

Letrozole is indicated as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer. Adjuvant treatment is given after primary treatment, such as surgery, to help reduce the risk of cancer recurrence.

2. Extended Adjuvant Treatment

Letrozole may be prescribed to eligible postmenopausal patients who have completed previous adjuvant tamoxifen treatment. Extended endocrine therapy may help reduce the risk of breast cancer recurrence in appropriately selected patients.

3. Advanced or Metastatic Breast Cancer

Letrozole is also used in the management of certain advanced or metastatic breast cancers in postmenopausal women, including hormone receptor-positive disease.

Treatment selection depends on previous therapies, disease characteristics, and the oncologist’s clinical judgment.

4. Other Specialist Uses

Letrozole is sometimes used off-label for ovulation induction in fertility treatment. This is a separate clinical application and should not be confused with its approved oncology indications. Such use requires specialist assessment and careful exclusion of an existing pregnancy.

Mechanism of Action – How Femroz Works

Letrozole works by inhibiting aromatase, an enzyme involved in converting androgens into estrogens.

After menopause, estrogen is produced mainly through aromatase activity in peripheral tissues rather than through the ovaries.

By blocking this enzyme, letrozole substantially reduces estrogen production. This decreases the hormonal stimulation of estrogen-dependent breast cancer cells and can help slow or control disease progression.

Letrozole does not directly destroy cancer cells in the same way as traditional cytotoxic chemotherapy. Instead, it is classified as endocrine or hormonal anticancer therapy.

Dosage and Administration

For approved breast cancer indications, the usual adult dosage of letrozole is 2.5 mg orally once daily, as directed by the treating physician.

The tablet may be taken with or without food.

Treatment duration varies according to the cancer stage, treatment objective, response, and the patient’s overall clinical condition.

Patients with severe liver impairment may require dosage adjustments and closer monitoring.

Patients should follow their prescribed treatment schedule and should not independently change the dose, interrupt treatment, or discontinue the medicine.

If a dose is missed, follow the prescribing information or contact the treating healthcare professional. Do not take a double dose to compensate for a missed tablet.

Contraindications and Important Precautions

Femroz should not be used in patients with known hypersensitivity to letrozole or any ingredient in the formulation.

Letrozole is contraindicated during pregnancy because it can cause fetal harm.

Important precautions include:

• Bone health: Long-term estrogen suppression may reduce bone mineral density and increase fracture risk.
• Cholesterol: Letrozole may increase blood cholesterol levels in some patients.
• Liver impairment: Severe hepatic dysfunction may affect drug exposure and require dosage adjustment.
• Dizziness and fatigue: Patients experiencing these symptoms should avoid driving or operating machinery until they know how the medicine affects them.
• Menopausal status: Use in patients who are not postmenopausal requires specialist consideration and is outside the standard approved breast cancer population.

Healthcare professionals may recommend bone density testing, cholesterol monitoring, and other assessments during treatment.

Possible Side Effects

As with other prescription medicines, Femroz may cause adverse reactions, although not every patient will experience them.

Commonly Reported Side Effects

• Hot flashes and increased sweating
• Joint pain and stiffness
• Muscle or bone pain
• Fatigue and weakness
• Headache or dizziness
• Nausea
• Swelling of the hands, feet, or ankles
• Increased blood cholesterol

Important Safety Risks

Long-term treatment may contribute to decreased bone mineral density, osteoporosis, and fractures.

Patients should seek prompt medical evaluation for severe allergic reactions, new or worsening chest pain, serious breathing difficulties, or other significant symptoms.

Any persistent or troublesome adverse effects should be discussed with the treating physician.

Drug Interactions

Letrozole may interact with other medicines that affect hormonal pathways or drug metabolism.

Estrogen-containing treatments may reduce its intended estrogen-suppressing effect.

Tamoxifen can reduce letrozole concentrations when used concurrently and is generally not combined with letrozole for standard endocrine treatment.

Patients should provide their healthcare professional with a complete list of prescription medicines, over-the-counter products, herbal preparations, and supplements before beginning treatment.

Pregnancy and Breastfeeding

Letrozole can cause harm to a developing fetus and must not be used during pregnancy.

Patients with reproductive potential should receive appropriate pregnancy assessment and contraceptive counseling when relevant. Effective contraception is recommended during treatment and for at least three weeks after the last dose, according to U.S. prescribing information.

Breastfeeding is not recommended during treatment or for at least three weeks following the final dose.

Storage and Handling

According to the supplied Femroz product listing, tablets should be stored below 30°C, protected from light and moisture.

Keep the medicine in its original packaging and out of the reach of children.

Always follow the storage conditions printed on the actual product package.

Manufacturer Information

Femroz 2.5 mg Tablet is listed as a pharmaceutical product manufactured by Everest Pharmaceuticals Ltd., Bangladesh.

It contains Letrozole 2.5 mg and is classified as a prescription hormonal anticancer medicine.

Product availability, packaging, registration status, and supply eligibility may vary by country.

Medical Disclaimer

This product information is intended for general educational purposes and does not replace professional medical advice, diagnosis, or treatment. Femroz is a prescription medicine and must be used only as directed by a qualified healthcare professional. Patients should consult their treating oncologist or pharmacist regarding appropriate use, monitoring, and potential adverse effects.